Brief: Knight Therapeutics Reports Fourth Quarter And Year-End 2021 Results
24/03/2022 11:37
March 24 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END
2021
RESULTS AND PROVIDES 2022 REVENUE GUIDANCE
* QTRLY DILUTED NET LOSS PER SHARE $0.07
* Q4 EARNINGS PER SHARE VIEW C$-0.00 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX5WDJ2C
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil